Tavira Tx
Introducing the next-generation AAV-targeting platform
How it works
We engineer a well-characterized parental AAV serotype to contain an enzyme recognition site.
​decorated AAV, dAAVe
Via enzymatic conjugation, we attach specific targeting groups.
Those could be chemical (small molecule) or biological
(e.g., nanobody, peptide, antibody fragment).
Advantages
Increased specificity
Our technology precisely targets specific human tissues or cell types, enhancing therapeutic outcomes while minimizing unwanted effects.
Higher potency
With improved efficacy, our decorated AAV particles require a lower dose to achieve clinical benefits, reducing the overall treatment burden.
Better manufacturing
Our platform ensures robust and scalable manufacturing processes, enabling consistent production at a higher standard.
Improved toxicity profile
Our technology significantly reduces off-target effects, improving safety for patients.
Lower cost
Efficient production and lower dosing result in shorter development timelines and reduced costs, making treatments accessible to a wider range of patients and conditions beyond rare diseases.